The RA NarRAtive gathered insights from physicians and patient perspectives in the management of RA through two global surveys which were fielded across 16 countries and responded to by 4,170 adults with self-reported RA and 1,736 physicians.

In reviewing and discussing the findings of both surveys, the RA NarRAtive global Advisory Panel suggests that people living with RA and healthcare providers can establish a new conversation around RA by recognizing the unique perspective of each person involved in patient care.

When developing disease management plans, consider the day-to-day experiences of people living with RA. Improved dialogue between physicians and patients may provide the opportunity for patients to more openly express any expectations or concerns, allowing physicians to take action on specific requirements of individual patients. Read more about the RA NarRAtive survey results and the unexpected impacts of living with RA as well as other aspects of disease management.¹

The RA NarRAtive Weighted Survey Methodology

The RA NarRAtive Patient Survey

The RA NarRAtive patient survey was fielded by Harris Poll across 16 countries from September 2014 to April 2016, and was replied to by 1,805 adults ages 18+ who have been diagnosed with rheumatoid arthritis (RA) in the U.S., and were primarily managed by a rheumatologist in Argentina (n=142), Australia (n=119), Brazil (n=163), Canada (n=67), France (n=64), Germany (n=171), Hong Kong (n=107), Italy (n=96), Japan (n=138), South Korea (n=127), Spain (n=59), Taiwan (n=45), Turkey (n=77), UK (n=66), and U.S. (n =192).¹

Results from the RA NarRAtive patient sample survey may not reflect the experiences of the broader RA population.

The RA NarRAtive Physician Survey

The RA NarRAtive physician survey was conducted online by Harris Poll on behalf of Pfizer between August 14-October 2, 2015 among 1,736 rheumatologists ages 18+ who have seen at least five (5) RA patients in the past month whose RA was moderate to severely active, in Argentina (n=130), Australia (n=60), Brazil (n=150), Canada (n=50), France (n=149), Germany (n=150), Hong Kong (n=30), Italy (n=100), Japan (n=139), South Korea (n=100), Spain (n=100), Taiwan (n=100)¹, Turkey (n=50), UK (n=150), and U.S. (n=208).¹

Physician results in the United States were weighted by region, years in practice, and physician gender. In all other countries, raw data were not weighted at the individual country level (sample sizes noted above), and therefore are only representative of the individuals who completed the survey. For the global, 16-country total, a post-weight was applied to adjust for the relative size of each country's adult population within the total adult population across all countries surveyed. The unweighted sample sizes above reflect the total number of HCPs who completed the survey in each country, while all reported percentages are calculated based on the weighted global total described here.

RA NarRAtive physician sample survey may not reflect the experiences of all rheumatologists. Raw data were not weighted at the individual country level (except in the United States), and are therefore only representative of the individuals who completed the survey.

Where permitted, some members of the Global RA NarRAtive Advisory Panel were paid honoraria for their participation. Pfizer provided travel and accommodation, as well as a compensation, to Advisory Panel members who represent patient advocacy organizations for time spent developing the survey and attending meetings to review the survey findings.

The above methodology reflects survey data published in BMC - Health and Quality of Life Outcomes (November 2018)